|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021713,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0031268,
umls-concept:C0032743,
umls-concept:C0046056,
umls-concept:C0087111,
umls-concept:C0150369,
umls-concept:C0392747,
umls-concept:C0392762,
umls-concept:C0443172,
umls-concept:C0549193,
umls-concept:C1261473,
umls-concept:C2003874
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-30
|
|
pubmed:abstractText |
Measurements of tumor glucose use by (18)F-FDG PET need to be standardized within and across institutions. Various parameters are used for measuring changes in tumor glucose metabolic activity with (18)F-FDG PET in response to cancer treatments. However, it is unknown which of these provide the lowest variability between observers. Knowledge of the interobserver variability of quantitative parameters is important in sarcomas as these tumors are frequently large and demonstrate heterogeneous (18)F-FDG uptake.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0161-5505
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1038-46
|
|
pubmed:meshHeading |
pubmed-meshheading:18552153-Adult,
pubmed-meshheading:18552153-Aged,
pubmed-meshheading:18552153-Aged, 80 and over,
pubmed-meshheading:18552153-Bone Neoplasms,
pubmed-meshheading:18552153-Chemotherapy, Adjuvant,
pubmed-meshheading:18552153-Female,
pubmed-meshheading:18552153-Fluorodeoxyglucose F18,
pubmed-meshheading:18552153-Glucose,
pubmed-meshheading:18552153-Humans,
pubmed-meshheading:18552153-Image Interpretation, Computer-Assisted,
pubmed-meshheading:18552153-Male,
pubmed-meshheading:18552153-Middle Aged,
pubmed-meshheading:18552153-Neoadjuvant Therapy,
pubmed-meshheading:18552153-Observer Variation,
pubmed-meshheading:18552153-Osteosarcoma,
pubmed-meshheading:18552153-Positron-Emission Tomography,
pubmed-meshheading:18552153-Radiopharmaceuticals,
pubmed-meshheading:18552153-Soft Tissue Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
|
|
pubmed:affiliation |
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, USA.
|
|
pubmed:publicationType |
Journal Article
|
